Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines – ExecEdge
Now Reading:
Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines
Full Article 50 second read

Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines

By Daniella Parra

Brii Biosciences and VBI Vaccines (NASDAQ: VBIV) said they will expand and control of BRII-179 supplies, a late-stage asset for HBV functional cure.

Initially, a $2.5 million promissory note will be issued, eliminating royalty and milestone payments for PreHevbri and upon meeting conditions, the note will increase to $10 million, securing VBI’s IP for BRII-179, Brii Bio said. The company said they plan to become VBI’s commercial supplier for PreHevbrio and PreHevbri.

“As Brii Bio transitions to late-stage development of HBV programs, a global manufacturing strategy becomes critically important. We look forward to working together with the biologics manufacturing experts at the Rehovot site and timely integration of our R&D and manufacturing capabilities,” said Dr. Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio.

Contact:

Healthcare Edge

Editor@Executives-edge.com

Leave a Reply

Your email address will not be published. Required fields are marked *

Input your search keywords and press Enter.